Significant prognostic cytogenetic risk groups identified by tree analysis for CR, DFS, and OS
Cytogenetic risk groups . | No. . | Outcome, % (95% CI)* . |
|---|---|---|
| Complete remission | ||
| Complex ≥3 | 122 | 25 (17-32) |
| Rare aberrations | 33 | 30 (15-46) |
| Noncomplex ≥3, nonrare aberrations | 480 | 56 (51-60) |
| Disease-free survival | ||
| Complex >5 | 22 | 0 |
| Fewer than 5 aberrations | 286 | 9.1 (6.1-12.8) |
| Overall survival | ||
| Complex ≥5 | 94 | 0 |
| CBF AML | 31 | 19.4 (7.9-34.6) |
| Rare aberrations | 33 | 0 |
| Fewer than 5 non-CBF AML, nonrare aberrations | 477 | 7.5 (5.4-10.1) |
Cytogenetic risk groups . | No. . | Outcome, % (95% CI)* . |
|---|---|---|
| Complete remission | ||
| Complex ≥3 | 122 | 25 (17-32) |
| Rare aberrations | 33 | 30 (15-46) |
| Noncomplex ≥3, nonrare aberrations | 480 | 56 (51-60) |
| Disease-free survival | ||
| Complex >5 | 22 | 0 |
| Fewer than 5 aberrations | 286 | 9.1 (6.1-12.8) |
| Overall survival | ||
| Complex ≥5 | 94 | 0 |
| CBF AML | 31 | 19.4 (7.9-34.6) |
| Rare aberrations | 33 | 0 |
| Fewer than 5 non-CBF AML, nonrare aberrations | 477 | 7.5 (5.4-10.1) |
The outcome data show the complete remission rate, the 5-year DFS, and the 5-year OS.